Stereotactic radiosurgery: Adjacent tissue injury and response after high-dose single fraction radiation-part II: Strategies for therapeutic enhancement, brain injury mitigation, and brain injury repair

Neurosurgery

Volumn 60, Issue 5, 2007, Pages 799-813

  Oh, Bryan C ^a,b   Liu, Charles Y ^a   Wang, Michael Y ^a   Pagnini, Paul G ^a   Yu, Cheng ^a   Apuzzo, Michael L J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b LAC USC MEDICAL CENTER   (United States)

Author keywords

Radiation enhancement; Radiation injury; Radiation potentiation; Radiation protection; Radiation repair; Radiosensitizer; Radiosurgery

Indexed keywords

BARBITURIC ACID DERIVATIVE; BROXURIDINE; EFAPROXIRAL; ERYTHROPOIETIN; GADOLINIUM TEXAPHYRIN; GANGLIOSIDE GM1; HOE 33342; LAZAROID; LONIDAMINE; METHOHEXITAL; METRONIDAZOLE; MISONIDAZOLE; PENTOBARBITAL; THIOPENTAL;

BRAIN INJURY; BRAIN METASTASIS; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; EVALUATION; EXTRACELLULAR MATRIX; GENE THERAPY; HUMAN; MEDICAL LITERATURE; NANOTECHNOLOGY; NERVE FIBER GROWTH; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; REVIEW; STEM CELL; STEREOTAXIC SURGERY;

BRAIN INJURIES; HUMANS; RADIATION INJURIES; RADIOSURGERY; RADIOTHERAPY DOSAGE;

EID: 34247631116     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000255454.28225.5C     Document Type: Review

References (87)

1. Abraham DJ, Wireko FC, Randad RS, Poyart C, Kister J, Bohn B, Liard JF, Kunert MP: Allosteric modifiers of hemoglobin: 2-[4-[[(3, 5-disubstituted anilino)carbonyl]methyl]phenoxy]-2-methylpropionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats. Biochemistry 31:9141-9149, 1992.
2. Adler JR Jr, Colombo F, Heilbrun MP, Winston K: Toward an expanded view of radiosurgery. Neurosurgery 55:1374-1376, 2004.
3. Akel G, Benard P, Canal P, Soula G: Distribution and tumor penetration properties of a radiosensitizer 2-[14C] misonidazole (Ro 07-0582), in mice and rats as studied by whole-body autoradiography. Cancer Chemother Pharmacol 17:121-126, 1986.
4. Alexander E 3rd, Moriarty TM, Davis RB, Wen PY, Fine HA, Black PM, Kooy HM, Loeffler JS: Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 87:34-40, 1995.
5. Bergenheim AT, Henriksson R, Piepmeier JM, Yoshida D: Estramustine in malignant glioma. J Neurooncol 30:81-89, 1996.
6. Bernstein M, Ginsberg H, Glen J: Protection of iodine-125 brachytherapy brain injury in the rat with the 21-aminosteroid U-74389F. Neurosurgery 31:923-928, 1992.
7. Boengler K, Schulz R, Heusch G: Connexin 43 signaling and cardioprotection. Heart 92:1724-1727, 2006.
8. Buatti JM, Friedman WA, Theele DP, Bova FJ, Mendenhall WM: The lazaroid U74389G protects normal brain from stereotactic radiosurgery-induced radiation injury. Int J Radiat Oncol Biol Phys 34:591-597, 1996.
9. Carde P, Timmerman R, Mehta MP, Koprowski CD, Ford J, Tishler RB, Miles D, Miller RA, Renschler MF: Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 19:2074-2083, 2001.
10. Castillo MH, Button TM, Doerr R, Homs MI, Pruett CW, Pearce JI: Effects of radiotherapy on mandibular reconstruction plates. Am J Surg 156:261-263, 1988.
11. Chang EL, Loeffler JS, Riese NE, Wen PY, Alexander E 3rd, Black PM, Coleman CN: Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma. Int J Radiat Oncol Biol Phys 40:65-70, 1998.
12. Cho SH: Estimation of tumour dose enhancement due to gold nanoparticles during typical radiation treatments: A preliminary Monte Carlo study. Phys Med Biol 50:N163-N173, 2005.
13. Curran WJ Jr, Scott CB, Weinstein AS, Martin LA, Nelson JS, Phillips TL, Murray K, Fischbach AJ, Yakar D, Schwade JG: Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyper-fractionated radiation therapy and carmustine: Areport of Radiation Therapy Oncology Group 83-02. J Clin Oncol 11:857-862, 1993.
14. DeAngelis LM, Currie VE, Kim JH, Krol G, O'Hehir MA, Farag FM, Young CW, Posner JB: The combined use of radiation therapy and lonidamine in the treatment of brain metastases. J Neurooncol 7:241-247, 1989.
15. Eyre HJ, Ohlsen JD, Frank J, LoBuglio AF, McCracken JD, Weatherall TJ, Mansfield CM: Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment metastatic cancer to brain. A Southwest Oncology Group study. J Neurooncol 2:325-330, 1984.
16. Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH, Broder GJ: Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14:831-838, 1988.
17. Gridley DS, Archambeau JO, Andres MA, Mao XW, Wright K, Slater JM: Tumor necrosis factor-alpha enhances antitumor effects of radiation against glioma xenografts. Oncol Res 9:217-227, 1997.
18. Guelman LR, Zorrilla Zubilete MA, Rios H, Dopico AM, Zieher LM: GM1 ganglioside treatment protects against long-term neurotoxic effects of neonatal X-irradiation on cerebellar cortex cytoarchitecture and motor function. Brain Res 858:303-311, 2000.
19. Hainfeld JF, Slatkin DN, Smilowitz HM: The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol 49:N309-N315, 2004.
20. Hall E: Radiobiology for the Radiologist. Philadelphia, Lippincott Williams and Wilkins, 2000.
21. Han SK, Brody SL, Crystal RG: Suppression of in vivo tumorigenicity of human lung cancer cells by retrovirus-mediated transfer of the human tumor necrosis factor-alpha cDNA. Am J Respir Cell Mol Biol 11:270-278, 1994.
22. Henriksson R, Malmstrom A, Bergstrom P, Bergh G, Trojanowski T, Andreasson L, Blomquist E, Jonsborg S, Edekling T, Salander P, Brannstrom T, Bergenheim AT: High-grade astrocytoma treated concomitantly with estramustine and radiotherapy. J Neurooncol 78:321-326, 2006.
23. Herold DM, Das IJ, Stobbe CC, Iyer RV, Chapman JD: Gold microspheres: A selective technique for producing biologically effective dose enhancement. Int J Radiat Biol 76:1357-1364, 2000.
24. Kavanagh BD, Khandelwal SR, Schmidt-Ullrich RK, Roberts JD, Shaw EG, Pearlman AD, Venitz J, Dusenbery KE, Abraham DJ, Gerber MJ: A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: Tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics. Int J Radiat Oncol Biol Phys 49:1133-1139, 2001.
25. Khandelwal SR, Randad RS, Lin PS, Meng H, Pittman RN, Kontos HA, Choi SC, Abraham DJ, Schmidt-Ullrich R: Enhanced oxygenation in vivo by allosteric inhibitors of hemoglobin saturation. Am J Physiol 265:H1450-H1453, 1993.
26. Khuntia D, Mehta M: Motexafin gadolinium: A clinical review of a novel radioenhancer for brain tumors. Expert Rev Anticancer Ther 4:981-989, 2004.
27. Kimler BF, Liu C, Evans RG, Morantz RA: Effect of pentobarbital on normal brain protection and on the response of 9L rat brain tumor to radiation therapy. J Neurosurg 79:577-583, 1993.
28. Komarnicky LT, Phillips TL, Martz K, Asbell S, Isaacson S, Urtasun R: A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys 20:53-58, 1991.
29. Kondziolka D, Flickinger JC, Bissonette DJ, Bozik M, Lunsford LD: Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms. Neurosurgery 41:776-785, 1997.
30. Kondziolka D, Mori Y, Martinez AJ, McLaughlin MR, Flickinger JC, Lunsford LD: Beneficial effects of the radioprotectant 21-aminosteroid U-74389G in a radiosurgery rat malignant glioma model. Int J Radiat Oncol Biol Phys 44:179-184, 1999.
31. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC: Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 45:427-434, 1999.
32. Kondziolka D, Somaza S, Flickinger JC, Claassen D, Lunsford LD: Cerebral radioprotective effects of high-dose pentobarbital evaluated in an animal radiosurgery model. Neurol Res 16:456-459, 1994.
33. Kondziolka D, Somaza S, Martinez AJ, Jacobsohn J, Maitz A, Lunsford LD, Flickinger JC: Radioprotective effects of the 21-aminosteroid U-74389G for stereotactic radiosurgery. Neurosurgery 41:203-208, 1997.
34. Landy H, Markoe A, Potter P, Lasalle G, Marini A, Savaraj N, Reis I, Heros D, Wangpaichitr M, Feun L: Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade glioma. J Neurooncol 67:215-220, 2004.
35. Leary SP, Liu CY, Apuzzo ML: Toward the emergence of nanoneurosurgery: Part III - Nanomedicine: Targeted nanotherapy, nanosurgery, and progress toward the realization of nanoneurosurgery. Neurosurgery 58:1009-1026, 2006.
36. Leary SP, Liu CY, Yu C, Apuzzo ML: Toward the emergence of nanoneurosurgery: Part I - Progress in nanoscience, nanotechnology, and the comprehension of events in the mesoscale realm. Neurosurgery 57:606-634, 2005.
37. Lederman G, Arbit E, Odaimi M, Lombardi E, Wrzolek M, Wronski M: Fractionated stereotactic radiosurgery and concurrent taxol in recurrent glioblastoma multiforme: Apreliminary report. Int J Radiat Oncol Biol Phys 40:661-666, 1998.
38. Liu CY, Apuzzo ML, Tirrell DA: Engineering of the extracellular matrix: Working toward neural stem cell programming and neurorestoration - Concept and progress report. Neurosurgery 52:1154-1167, 2003.
39. Liu CY, Spicer M, Apuzzo ML: The genesis of neurosurgery and the evolution of the neurosurgical operative environment: Part II - Concepts for future development, 2003 and beyond. Neurosurgery 52:20-35, 2003.
40. Lomax NJ, Scheib SG: Quantifying the degree of conformity in radiosurgery treatment planning. Int J Radiat Oncol Biol Phys 55:1409-1419, 2003.
41. Lyubimova NV, Coultas PG, Yuen K, Martin RF: In vivo radioprotection of mouse brain endothelial cells by Hoechst 33342. Br J Radiol 74:77-82, 2001.
42. Marconi P, Tamura M, Moriuchi S, Krisky DM, Niranjan A, Goins WF, Cohen JB, Glorioso JC: Connexin 43-enhanced suicide gene therapy using herpesviral vectors. Mol Ther 1:71-81, 2000.
43. McDermott MW, Sneed PK: Radiosurgery in metastatic brain cancer. Neurosurgery 57 [Suppl 5]:S45-S54, 2005.
44. Mehta MP, Khuntia D: Current strategies in whole-brain radiation therapy for brain metastases. Neurosurgery 57 [Suppl 5]:S33-S44, 2005.
45. Mehta MP, Rodrigus P, Terhaard CH, Rao A, Suh J, Roa W, Souhami L, Bezjak A, Leibenhaut M, Komaki R, Schultz C, Timmerman R, Curran W, Smith J, Phan SC, Miller RA, Renschler MF: Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21:2529-2536, 2003.
46. Mehta MP, Shapiro WR, Glantz MJ, Patchell RA, Weitzner MA, Meyers CA, Schultz CJ, Roa WH, Leibenhaut M, Ford J, Curran W, Phan S, Smith JA, Miller RA, Renschler MF: Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: Centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 20:3445-3453, 2002.
47. Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, Kunkler I, Caudrelier JM, Eisenberg PD, Meerwaldt J, Siemers R, Carrie C, Gaspar LE, Curran W, Phan SC, Miller RA, Renschler MF: Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: Results of a randomized phase III trial. J Clin Oncol 22:157-165, 2004.
48. Monje ML, Mizumatsu S, Fike JR, Palmer TD: Irradiation induces neural precursor-cell dysfunction. Nat Med 8:955-962, 2002.
49. Monje ML, Palmer T: Radiation injury and neurogenesis. Curr Opin Neurol 16:129-134, 2003.
50. Nakahara N, Okada H, Witham TF, Attanucci J, Fellows WK, Chambers WH, Niranjan A, Kondziolka D, Pollack IF: Combination of stereotactic radio-surgery and cytokine gene-transduced tumor cell vaccination: A new strategy against metastatic brain tumors. J Neurosurg 95:984-989, 2001.
51. Nakase T, Fushiki S, Naus CC: Astrocytic gap junctions composed of connexin 43 reduce apoptotic neuronal damage in cerebral ischemia. Stroke 34:1987-1993, 2003.
52. Nedzi LA, Kooy H, Alexander E 3rd, Gelman RS, Loeffler JS: Variables associated with the development of complications from radiosurgery of intracranial tumors. Int J Radiat Oncol Biol Phys 21:591-599, 1991.
53. Niranjan A, Gobbel GT, Kondziolka D, Flickinger JC, Lunsford LD: Experimental radiobiological investigations into radiosurgery: Present understanding and future directions. Neurosurgery 55:495-505, 2004.
54. Niranjan A, Moriuchi S, Lunsford LD, Kondziolka D, Flickinger JC, Fellows W, Rajendiran S, Tamura M, Cohen JB, Glorioso JC: Effective treatment of experimental glioblastoma by HSV vector-mediated TNF alpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration. Mol Ther 2:114-120, 2000.
55. Niranjan A, Wolfe D, Tamura M, Soares MK, Krisky DM, Lunsford LD, Li S, Fellows-Mayle W, DeLuca NA, Cohen JB, Glorioso JC: Treatment of rat gliosarcoma brain tumors by HSV-based multigene therapy combined with radiosurgery. Mol Ther 8:530-542, 2003.
56. Nwokedi EC, DiBiase SJ, Jabbour S, Herman J, Amin P, Chin LS: Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme. Neurosurgery 50:41-47, 2002.
57. Okada H, Giezeman-Smits KM, Tahara H, Attanucci J, Fellows WK, Lotze MT, Chambers WH, Bozik ME: Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine. Gene Ther 6:219-226, 1999.
58. Oldfield EH, Friedman R, Kinsella T, Moquin R, Olson JJ, Orr K, DeLuca AM: Reduction in radiation-induced brain injury by use of pentobarbital or lidocaine protection. J Neurosurg 72:737-744, 1990.
59. Olson JJ, Shelley C, Orr K, DeLaney T, Oldfield EH: The cerebral radioprotective effect of alternative barbiturates to pentobarbital. Neurosurgery 30:720-723, 1992.
60. Owen-Schaub LB, Gutterman JU, Grimm EA: Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: Effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. Cancer Res 48:788-792, 1988.
61. Pearson RA, Luneborg NL, Becker DL, Mobbs P: Gap junctions modulate interkinetic nuclear movement in retinal progenitor cells. J Neurosci 25:10803-10814, 2005.
62. Phillips TL, Scott CB, Leibel SA, Rotman M, Weigensberg IJ: Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: Report of RTOG trial 89-05. Int J Radiat Oncol Biol Phys 33:339-348, 1995.
63. Pollock BE, Garces YI, Stafford SL, Foote RL, Schomberg PJ, Link MJ: Stereotactic radiosurgery for cavernous malformations. J Neurosurg 93:987-991, 2000.
64. Prados MD, Larson DA, Lamborn K, McDermott MW, Sneed PK, Wara WM, Chang SM, Mack EE, Krouwer HG, Chandler KL, Warnick RE, Davis RL, Rabbitt JE, Malec M, Levin VA, Gutin PH, Phillips TL, Wilson CB: Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors. Int J Radiat Oncol Biol Phys 40:57-63, 1998.
65. Prados MD, Scott CB, Rotman M, Rubin P, Murray K, Sause W, Asbell S, Comis R, Curran W, Nelson J, Davis RL, Levin VA, Lamborn K, Phillips TL: Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: A retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 40:653-659, 1998.
66. Prados MD, Seiferheld W, Sandler HM, Buckner JC, Phillips T, Schultz C, Urtasun R, Davis R, Gutin P, Cascino TL, Greenberg HS, Curran WJ Jr: Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: Final report of RTOG 9404. Int J Radiat Oncol Biol Phys 58:1147-1152, 2004.
67. Prang P, Muller R, Eljaouhari A, Heckmann K, Kunz W, Weber T, Faber C, Vroemen M, Bogdahn U, Weidner N: The promotion of oriented axonal regrowth in the injured spinal cord by alginate-based anisotropic capillary hydrogels. Biomaterials 27:3560-3569, 2006.
68. Riese NE, Loeffler JS, Wen P, Alexander E 3rd, Black PM, Coleman CN: A phase I study of etanidazole and radiotherapy in malignant glioma. Int J Radiat Oncol Biol Phys 29:617-620, 1994.
69. Rodrigus P: Motexafin gadolinium: A possible new radiosensitiser. Expert Opin Investig Drugs 12:1205-1210, 2003.
70. Sampson JH, Archer GE, Ashley DM, Fuchs HE, Hale LP, Dranoff G, Bigner DD: Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci U S A 93:10399-10404, 1996.
71. Schwentner C, Oswald J, Lunacek A, Fritsch H, Deibl M, Bartsch G, Radmayr C: Loss of interstitial cells of Cajal and gap junction protein connexin 43 at the vesicoureteral junction in children with vesicoureteral reflux. J Urol 174:1981-1986, 2005.
72. Senzer N: Rationale for a phase III study of erythropoietin as a neurocognitive protectant in patients with lung cancer receiving prophylactic cranial irradiation. Semin Oncol 29 [Suppl 6]:47-52, 2002.
73. Shafman TD, Loeffler JS: Novel radiation technologies for malignant gliomas. Curr Opin Oncol 11:147-151, 1999.
74. Shaw E, Scott C, Suh J, Kadish S, Stea B, Hackman J, Pearlman A, Murray K, Gaspar L, Mehta M, Curran W, Gerber M: RSR13 plus cranial radiation therapy in patients with brain metastases: Comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. J Clin Oncol 21:2364-2371, 2003.
75. Silva GA, Czeisler C, Niece KL, Beniash E, Harrington DA, Kessler JA, Stupp SI: Selective differentiation of neural progenitor cells by high-epitope density nanofibers. Science 303:1352-1355, 2004.
76. Sims EC, Plowman PN: Stereotactic radiosurgery XII. Large AVM and the failure of the radiation response modifier gamma linolenic acid to improve the therapeutic ratio. Br J Neurosurg 15:28-34, 2001.
77. Smith SL, Scherch HM, Hall ED: Protective effects of tirilazad mesylate and metabolite U-89678 against blood-brain barrier damage after subarachnoid hemorrhage and lipid peroxidative neuronal injury. J Neurosurg 84:229-233, 1996.
78. Staba MJ, Mauceri HJ, Kufe DW, Hallahan DE, Weichselbaum RR: Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther 5:293-300, 1998.
79. Suh JH: Efaproxiral: Anovel radiation sensitiser. Expert Opin Investig Drugs 13:543-550, 2004.
80. Suh JH, Stea B, Nabid A, Kresl JJ, Fortin A, Mercier JP, Senzer N, Chang EL, Boyd AP, Cagnoni PJ, Shaw E: Phase III study of Efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol 24:106-114, 2006.
81. Tada E, Parent JM, Lowenstein DH, Fike JR: X-irradiation causes a prolonged reduction in cell proliferation in the dentate gyrus of adult rats. Neuroscience 99:33-41, 2000.
82. Tada E, Yang C, Gobbel GT, Lamborn KR, Fike JR: Long-term impairment of subependymal repopulation following damage by ionizing irradiation. Exp Neurol 160:66-77, 1999.
83. Ulm AJ 3rd, Friedman WA, Bradshaw P, Foote KD, Bova FJ: Radiosurgery in the treatment of malignant gliomas: The University of Florida experience. Neurosurgery 57:512-517, 2005.
84. Vallbo C, Bergenheim T, Hedman H, Henriksson R: The antimicrotubule drug estramustine but not irradiation induces apoptosis in malignant glioma involving AKT and caspase pathways. J Neurooncol 56:143-148, 2002.
85. Voges J, Treuer H, Sturm V, Buchner C, Lehrke R, Kocher M, Staar S, Kuchta J, Muller RP: Risk analysis of linear accelerator radiosurgery. Int J Radiat Oncol Biol Phys 36:1055-1063, 1996.
86. Wakimoto H, Abe J, Tsunoda R, Aoyagi M, Hirakawa K, Hamada H: Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res 56:1828-1833, 1996.
87. Yoshida D, Piepmeier J, Weinstein M: Estramustine sensitizes human glioblastoma cells to irradiation. Cancer Res 54:1415-1417, 1994.